Government scientists have warned that the substances haven’t proven to be safe or effective. A panel of federal health advisers on Thursday narrowly recommended easing access to several peptides popular with wellness influencers and celebrities, despite warnings from government scientists that the chemicals haven’t been shown to be safe or effective.In a series of votes, outside experts to the Food and Drug Administration advised the agency to drop current restrictions barring pharmacies from producing injectable peptides with names including BPC-157, TB-500 and KPV.The panel’s vote is not binding but is likely to embolden Health Secretary Robert F. Kennedy Jr., who has described himself as a “big fan” of peptides and vowed to overturn FDA restrictions put in place under President Joe Biden.Across several votes, the panelists voted 8-6, with one abstention, in favor of putting the peptides on FDA’s list of substances considered safe for pharmacy compounding. If FDA follows that advice, telehealth companies are expected to ramp up marketing of the chemicals for wellness and cosmetic uses.Thursday’s vote tally reflected the unusual makeup of the panel. Prior to the meeting, more than a half-dozen people with connections to the peptide industry were added to the group, including doctors, pharmacists or consultants who work in the field.“I voted yes because it’s time to put this decision back in the hands of the patient, the physician and the pharmacist,” said David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, after the vote on BPC-157.The panel will vote Friday on three more peptides. The FDA isn’t required to follow the group’s advice, though it usually does.
Peptide drugs popular with influencers get backed by FDA panel, despite warnings from scientists
Why This Matters
The FDA advisory panel's recommendation to ease restrictions on certain peptides popular with influencers marks a significant shift in regulatory oversight, potentially increasing access and marketing of these substances despite ongoing safety concerns. This development could influence the future of wellness products, telehealth services, and consumer safety in the biotech industry.
Key Takeaways
- Panel recommends easing restrictions on peptides like BPC-157, TB-500, and KPV.
- FDA's decision could lead to increased marketing and availability of peptide-based wellness products.
- Safety concerns remain, as government scientists have warned about the lack of proven safety and efficacy.
Get alerts for these topics